Scott Youngstrom Named Chief Financial Officer of Enpath Medical
July 05 2006 - 1:42PM
PR Newswire (US)
MINNEAPOLIS, July 5 /PRNewswire-FirstCall/ -- Enpath Medical, Inc.
(NASDAQ:NPTH) announced today that Scott P. Youngstrom has been
named Chief Financial Officer. Mr. Youngstrom brings 20 years of
financial experience in a variety of medical device companies, most
recently as Vice President and Chief Financial Officer of Compex
Technologies, Inc., a publicly traded company engaged in electronic
muscle stimulation devices until it was acquired earlier in 2006.
Mr. Youngstrom replaces James D. Hartman as the Company's CFO. Mr.
Hartman retired as Chief Executive Officer in January 2006, and
with Mr. Youngstrom's addition, will now serve solely as Chairman
of the Board of Directors. Mr. Hartman has been the Company's Chief
Financial Officer since 1991 and had been the Chief Executive
Officer since 1996 when John C. Hertig joined the Company. "I
believe Scott will be a great addition to our management team,"
said Mr. Hertig, Chief Executive Officer. "He not only brings
public company financial experience, but his background in medical
devices has familiarized him with many of the same analysts and
institutional investors that Enpath has cultivated over the last
several years. He also brings experience in capital- raising and
acquisitions that will be beneficial to our company as we execute
our growth strategy in the years ahead." Prior to joining Compex
Technologies in 2002, Mr. Youngstrom served as Vice President and
Chief Financial Officer of Acist Medical Systems, Inc., a privately
held Twin Cities based medical device company engaged in the
manufacture and marketing of cardiovascular devices. Mr. Youngstrom
also held financial positions with Cardiotronics Systems, Inc. and
Alaris Medical. Mr. Youngstrom started his career with Price
Waterhouse Coopers and is a Certified Public Accountant. He holds
an accounting degree from the University of Northern Iowa. About
Enpath Medical Enpath Medical, Inc., headquartered in Plymouth,
Minnesota, is a leader in the design, development, manufacture and
marketing of percutaneous delivery systems and stimulation leads
technologies. Its proprietary products include venous vessel
introducers, articulating and fixed curve delivery catheters,
epicardial and endocardial stimulation leads, and other products
for use in pacemaker, defibrillator, catheter and infusion port
procedures as well as neuromodulation markets. Its products, which
are primarily finished goods, are sold worldwide through partnering
relationships with other medical device companies. DATASOURCE:
Enpath Medical, Inc. CONTACT: Doug Sherk, +1-415-896-6820, or
Jennifer Beugelmans, +1-415-896-6820, both of EVC Group, for Enpath
Medical Web site: http://www.enpathmed.com/
Copyright
Enpath (NASDAQ:NPTH)
Historical Stock Chart
From Jul 2024 to Aug 2024
Enpath (NASDAQ:NPTH)
Historical Stock Chart
From Aug 2023 to Aug 2024